| The oncogenic transcription factor RUNX1/ETO corrupts cell cycle regulation to drive leukemic transformation N Martinez-Soria, L McKenzie, J Draper, A Ptasinska, H Issa, S Potluri, ... Cancer Cell 34 (4), 626-642. e8, 2018 | 103 | 2018 |
| Dysregulated metabolism in cancer A Isa Biomedical Research and Therapy 9 (8), 5201-5208, 2022 | 5 | 2022 |
| Identification of glycolytic pathway as RUNX1/ETO-dependent for propagation and survival A Isa, N Martinez-Soria, L McKenzie, H Blair, H Issa, S Luli, S Nakjang, ... Klinische Pädiatrie 230 (03), 3, 2018 | 2 | 2018 |
| CCND2 is a RUNX1/ETO target required for leukaemic propagation N Martinez-Soria, L McKenzie, S Nakjang, V Forster, A Isa, HJ Blair, ... Klinische Pädiatrie 229 (03), A10, 2017 | 1 | 2017 |
| COVID-19: RISK, CLINICAL OUTCOMES AND MECHANISM AMONG PATIENTS WITH CANCER: Received 2023-01-03; Accepted 2023-04-11; Published 2023-06-06 A Isa, HNM Nazman Journal of Health and Translational Medicine (JUMMEC), 374-379, 2023 | | 2023 |
| Human bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukaemia D Pal, H Blair, S Boyd, AH Sharon, S Nizami, A Isa, M Beckett, R Nelson, ... bioRxiv, 2021.06. 18.448490, 2021 | | 2021 |
| Functional characterisation of SLC2A3 and PFKP in t (8; 21)-positive acute myeloid leukemia A Isa Newcastle University, 2019 | | 2019 |
| Investigating the Mechanisms of Methotrexate Neurotoxicity in Patients Under Treatment for Childhood Leukemia and Long-Term Survivors V Forster, J Carr-Wilkinson, H Issa, A Isa, S Nakjang, D Tweddle, ... PEDIATRIC BLOOD & CANCER 65, S506-S506, 2018 | | 2018 |
| The oncogenic transcription factor RUNX1/ETO corrupts the cell cycle to drive leukaemic transformation L McKenzie, N Martinez-Soria, HJ Blair, H Issa, A Isa, R Tirtakusuma, ... Klinische Pädiatrie 230 (03), 37, 2018 | | 2018 |
